Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study☆
Under a Creative Commons license
open access
Keywords
Adult congenital heart disease
Anticoagulation
NOACs
Thromboembolism
Bleeding
Valvular disease
Cited by (0)
- ☆
All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
© 2019 The Authors. Published by Elsevier B.V.